Bayer's Kerendia Wins FDA Approval As First New CKD Treatment For Type 1 Diabetes In 30 Years

The U.S. FDA approved Bayer's Kerendia for adults with chronic kidney disease associated with type 1 diabetes, marking the first new treatment for this indication in more than three decades. The approval expands Kerendia's addressable market and provides Bayer with a potentially meaningful new growth opportunity in renal and diabetes care.